These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 27509825)

  • 21. Latent heparanase facilitates VLA-4-mediated melanoma cell binding and emerges as a relevant target of heparin in the interference with metastatic progression.
    Gerber U; Hoß SG; Shteingauz A; Jüngel E; Jakubzig B; Ilan N; Blaheta R; Schlesinger M; Vlodavsky I; Bendas G
    Semin Thromb Hemost; 2015 Mar; 41(2):244-54. PubMed ID: 25682080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD14 is a ligand for the integrin alpha4beta1.
    Humphries JD; Humphries MJ
    FEBS Lett; 2007 Feb; 581(4):757-63. PubMed ID: 17274987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma.
    Monnier Y; Farmer P; Bieler G; Imaizumi N; Sengstag T; Alghisi GC; Stehle JC; Ciarloni L; Andrejevic-Blant S; Moeckli R; Mirimanoff RO; Goodman SL; Delorenzi M; Rüegg C
    Cancer Res; 2008 Sep; 68(18):7323-31. PubMed ID: 18794119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYR61 triggers osteosarcoma metastatic spreading via an IGF1Rβ-dependent EMT-like process.
    Habel N; Stefanovska B; Carène D; Patiño-Garcia A; Lecanda F; Fromigué O
    BMC Cancer; 2019 Jan; 19(1):62. PubMed ID: 30642298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fibronectin promotes cell proliferation of human pre-B cell line via its interactions with VLA-4 and VLA-5.
    Harima A; Nakaseko C; Yokota A; Kitagawa M; Morimoto C; Harigaya K; Saito Y
    Hematology; 2008 Aug; 13(4):236-43. PubMed ID: 18796250
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYR61 (CCN1) is a metastatic biomarker of gastric cardia adenocarcinoma.
    Wei J; Yu G; Shao G; Sun A; Chen M; Yang W; Lin Q
    Oncotarget; 2016 May; 7(21):31067-78. PubMed ID: 27105510
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thymic epithelial cell expansion through matricellular protein CYR61 boosts progenitor homing and T-cell output.
    Emre Y; Irla M; Dunand-Sauthier I; Ballet R; Meguenani M; Jemelin S; Vesin C; Reith W; Imhof BA
    Nat Commun; 2013; 4():2842. PubMed ID: 24280864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement of VLA-4/CS-1 and VLA-4/VCAM adhesion inhibition.
    Mehlin C
    Curr Protoc Pharmacol; 2004 May; Chapter 12():Unit 12.7. PubMed ID: 22294119
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell adhesion to anosmin via α5β1, α4β1, and α9β1 integrins.
    Endo Y; Ishiwata-Endo H; Yamada KM
    Cell Adh Migr; 2018 Mar; 12(2):93-100. PubMed ID: 27715389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparin inhibits sickle erythrocyte adhesion to VCAM-1 through VLA-4 blockade in a standardized microfluidic flow adhesion assay.
    Lancelot M; White J; Sarnaik S; Hines P
    Br J Haematol; 2017 Aug; 178(3):479-481. PubMed ID: 27341635
    [No Abstract]   [Full Text] [Related]  

  • 31. Preliminary evaluation of
    Roxin Á; Zhang C; Huh S; Lepage ML; Zhang Z; Lin KS; Bénard F; Perrin DM
    Nucl Med Biol; 2018 Jun; 61():11-20. PubMed ID: 29597141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
    Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyr61-positive cancer stem-like cells enhances distal metastases of pancreatic cancer.
    Shi W; Zhang C; Chen Z; Chen H; Liu L; Meng Z
    Oncotarget; 2016 Nov; 7(45):73160-73170. PubMed ID: 27705906
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Involvement of Cyr61 in growth, migration, and metastasis of prostate cancer cells.
    Sun ZJ; Wang Y; Cai Z; Chen PP; Tong XJ; Xie D
    Br J Cancer; 2008 Nov; 99(10):1656-67. PubMed ID: 18941464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells.
    Rho SB; Woo JS; Chun T; Park SY
    Biotechnol Lett; 2009 Jan; 31(1):23-8. PubMed ID: 18800188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemerin contributes to inflammation by promoting macrophage adhesion to VCAM-1 and fibronectin through clustering of VLA-4 and VLA-5.
    Hart R; Greaves DR
    J Immunol; 2010 Sep; 185(6):3728-39. PubMed ID: 20720202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Energy landscape differences among integrins establish the framework for understanding activation.
    Li J; Springer TA
    J Cell Biol; 2018 Jan; 217(1):397-412. PubMed ID: 29122968
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Beaino W; Nedrow JR; Anderson CJ
    Mol Pharm; 2015 Jun; 12(6):1929-38. PubMed ID: 25919487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Snail/FOXK1/Cyr61 Signaling Axis Regulates the Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.
    Huang X; Xiang L; Li Y; Zhao Y; Zhu H; Xiao Y; Liu M; Wu X; Wang Z; Jiang P; Qing H; Zhang Q; Liu G; Zhang W; Li A; Chen Y; Liu S; Wang J
    Cell Physiol Biochem; 2018; 47(2):590-603. PubMed ID: 29794466
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of beta 1 integrin intracytoplasmic domains in the regulation of VLA-4-mediated adhesion of human T cells to VCAM-1 under flow conditions.
    Rosenthal-Allieri MA; Ticchioni M; Breittmayer JP; Shimizu Y; Bernard A
    J Immunol; 2005 Jul; 175(2):1214-23. PubMed ID: 16002725
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.